Literature DB >> 33052761

Pluripotent Stem Cell-Based Organoid Technologies for Developing Next-Generation Vision Restoration Therapies of Blindness.

Ratnesh K Singh1, Francois Binette1, Magdalene Seiler2,3,4,5, Simon M Petersen-Jones6, Igor O Nasonkin1.   

Abstract

Blindness, associated with death of retinal cells at the back of the eye, is caused by a number of conditions with high prevalence such as glaucoma, age-related macular degeneration, and diabetic retinopathy. In addition, a large number of orphan inherited (mostly monogenic) conditions, such as retinitis pigmentosa and Leber Congenital Amaurosis, add to the overall number of patients with blinding retinal degenerative diseases. Blindness caused by deterioration and loss of retina is so far incurable. Modern biomedical research leveraging molecular and regenerative medicine approaches had a number of groundbreaking discoveries and proof-of-principle treatments of blindness in animals. However, these methods are slow to be standardized and commercialized as therapies to benefit people losing their eyesight due to retinal degenerative conditions. In this review, we will outline major regenerative medicine approaches, which are emerging as promising for preserving or/and restoring vision. We discuss the potential of each of these approaches to reach commercialization step and be converted to treatments, which could at least ameliorate blindness caused by retinal cell death.

Entities:  

Keywords:  blindness; cell therapy; organoids; photoreceptors; retina; retinal degeneration; vision

Mesh:

Year:  2020        PMID: 33052761      PMCID: PMC8060716          DOI: 10.1089/jop.2020.0016

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  104 in total

1.  With injectable biologic therapies on the rise, payers face tough reimbursement issues.

Authors: 
Journal:  Biotechnol Healthc       Date:  2010

Review 2.  Reaching the brain: Advances in optic nerve regeneration.

Authors:  Larry I Benowitz; Zhigang He; Jeffrey L Goldberg
Journal:  Exp Neurol       Date:  2015-12-31       Impact factor: 5.330

3.  Embryonic stem cell trials for macular degeneration: a preliminary report.

Authors:  Steven D Schwartz; Jean-Pierre Hubschman; Gad Heilwell; Valentina Franco-Cardenas; Carolyn K Pan; Rosaleen M Ostrick; Edmund Mickunas; Roger Gay; Irina Klimanskaya; Robert Lanza
Journal:  Lancet       Date:  2012-01-24       Impact factor: 79.321

4.  The arrival of average sale price.

Authors:  Patrick Mullen
Journal:  Biotechnol Healthc       Date:  2007-06

Review 5.  Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.

Authors:  Giuseppe Pasqualetti; Romano Danesi; Mario Del Tacca; Guido Bocci
Journal:  Pharmacogenomics       Date:  2007-01       Impact factor: 2.533

6.  Human neural retinal transplantation.

Authors:  M S Humayun; E de Juan; M del Cerro; G Dagnelie; W Radner; S R Sadda; C del Cerro
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-09       Impact factor: 4.799

7.  Pharmacological Modulation of Photoreceptor Outer Segment Degradation in a Human iPS Cell Model of Inherited Macular Degeneration.

Authors:  Ruchira Singh; David Kuai; Karina E Guziewicz; Jackelyn Meyer; Molly Wilson; Jianfeng Lu; Molly Smith; Eric Clark; Amelia Verhoeven; Gustavo D Aguirre; David M Gamm
Journal:  Mol Ther       Date:  2015-08-24       Impact factor: 11.454

8.  Immunosuppressive Treatment Can Alter Visual Performance in the Royal College of Surgeons Rat.

Authors:  Ann E Cooper; Jang-Hyeon Cho; Steven Menges; Sahar Masood; Jun Xie; Jing Yang; Henry Klassen
Journal:  J Ocul Pharmacol Ther       Date:  2016-03-23       Impact factor: 2.671

Review 9.  The form and function of channelrhodopsin.

Authors:  Karl Deisseroth; Peter Hegemann
Journal:  Science       Date:  2017-09-15       Impact factor: 47.728

10.  Long-Term Efficacy of GMP Grade Xeno-Free hESC-Derived RPE Cells Following Transplantation.

Authors:  Trevor J McGill; Osnat Bohana-Kashtan; Jonathan W Stoddard; Michael D Andrews; Neelay Pandit; Lior R Rosenberg-Belmaker; Ofer Wiser; Limor Matzrafi; Eyal Banin; Benjamin Reubinoff; Nir Netzer; Charles Irving
Journal:  Transl Vis Sci Technol       Date:  2017-06-14       Impact factor: 3.283

View more
  2 in total

Review 1.  Retinal Cell Transplantation, Biomaterials, and In Vitro Models for Developing Next-generation Therapies of Age-related Macular Degeneration.

Authors:  Lawrence J Rizzolo; Igor O Nasonkin; Ron A Adelman
Journal:  Stem Cells Transl Med       Date:  2022-03-31       Impact factor: 6.940

2.  Comparison of Developmental Dynamics in Human Fetal Retina and Human Pluripotent Stem Cell-Derived Retinal Tissue.

Authors:  Ratnesh K Singh; Paige A Winkler; Francois Binette; Simon M Petersen-Jones; Igor O Nasonkin
Journal:  Stem Cells Dev       Date:  2021-04       Impact factor: 3.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.